Odelia BenShitrit - Enlivex Therapeutics Head of Clinical Operations
| ENLV Stock | ILA 397.00 1.50 0.38% |
Insider
Odelia BenShitrit is Head of Clinical Operations of Enlivex Therapeutics
| Phone | (972) 2 6208070 |
| Web | www.enlivex.com |
Enlivex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1888) % which means that it has lost $0.1888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.378) %, meaning that it generated substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Avi Zakay | Magic Software Enterprises | 40 | |
| Yehuda Reznik | Hiron Trade Investments Industr | 70 | |
| Dorit Zion | Hiron Trade Investments Industr | N/A | |
| Nachman CPA | First International Bank | N/A | |
| Yosef Yitzchak | Hiron Trade Investments Industr | 70 | |
| Keren Dickman | Meitav Dash Investments | 53 | |
| Karin Netzer | Magic Software Enterprises | N/A | |
| Boaz Aviv | Blender Financial Technologies | 36 | |
| Adi Kaplan | Israel Discount Bank | 50 | |
| Benzi CPA | First International Bank | N/A | |
| Einat CPA | Meitav Dash Investments | 56 | |
| Liran Razmovich | Israel Discount Bank | N/A | |
| CPA CPA | First International Bank | N/A | |
| Hanan MBA | Magic Software Enterprises | 71 | |
| Advocate Dahan | First International Bank | N/A | |
| Neil Amir | Hiron Trade Investments Industr | 37 | |
| Yonatan LeAri | Hiron Trade Investments Industr | 47 | |
| Amir Birenboim | First International Bank | N/A | |
| Lena Schwartz | Israel Discount Bank | N/A | |
| Ester Levy | Hiron Trade Investments Industr | 58 | |
| Lissa Baum | Israel Discount Bank | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 |
Enlivex Therapeutics Leadership Team
Elected by the shareholders, the Enlivex Therapeutics' board of directors comprises two types of representatives: Enlivex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enlivex. The board's role is to monitor Enlivex Therapeutics' management team and ensure that shareholders' interests are well served. Enlivex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enlivex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Abraham Havron, Independent Director | ||
| Shai Novik, Executive Chairman of the Board | ||
| Dror Mevorach, Chief Executive Officer, Founder, Chief Scientific Officer | ||
| Shachar Shlosberger, Chief Financial Officer | ||
| Odelia BenShitrit, Head of Clinical Operations | ||
| Sangwoo Lee, Director | ||
| Oren Hershkovitz, Chief Executive Officer | ||
| Baruch Halpert, Director | ||
| Michel Habib, Director | ||
| Shai MBA, Ex Chairman | ||
| Pr MD, Founder Officer | ||
| Veronique AmorBaroukh, Head CMC | ||
| Shachar CPA, Chief Officer | ||
| Gili Hart, Independent Director | ||
| Brian Schwartz, Director | ||
| Bernhard Kirschbaum, Director | ||
| Sigal Arad, Director HR | ||
| Hyun Lee, Director |
Enlivex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enlivex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 147.66 M | |||
| Shares Outstanding | 18.41 M | |||
| Shares Owned By Insiders | 12.19 % | |||
| Shares Owned By Institutions | 9.53 % | |||
| Price To Book | 1.23 X | |||
| EBITDA | (18.74 M) | |||
| Net Income | (14.47 M) | |||
| Cash And Equivalents | 90.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Enlivex Stock
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.